The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Medicines met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share shrank significantly.
Gross margins grew, operating margins increased, net margins shrank.
Medicines booked revenue of $136.8 million. The five analysts polled by S&P Capital IQ wanted to see sales of $136.5 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $120.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.40. The four earnings estimates compiled by S&P Capital IQ predicted $0.39 per share. GAAP EPS of $0.17 for Q3 were 87% lower than the prior-year quarter's $1.34 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.0%, 70 basis points better than the prior-year quarter. Operating margin was 11.0%, 150 basis points better than the prior-year quarter. Net margin was 6.8%, 5,330 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $146.5 million. On the bottom line, the average EPS estimate is $0.42.
Next year's average estimate for revenue is $546.2 million. The average EPS estimate is $1.40.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 131 members out of 145 rating the stock outperform, and 14 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give Medicines a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medicines is outperform, with an average price target of $27.40.
- Add Medicines to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.